Simona Pagliuca, MD, PhD, Nancy University Hospital, Nancy, France, provides an overview of current research on aplastic anemia treatment. The Phase III RACE trial (NCT02099747) demonstrates the efficacy of eltrombopag in combination with horse antithymocyte globulin (ATG) and cyclosporine A. Other thrombopoietin (TPO) receptor agonists, ruxolitinib, and anti-interleukin-2 antibodies also show promise, particularly in the relapsed/refractory (R/R) setting. Dr Pagliuca also addresses transplant-related strategies and the challenges faced by transplant-ineligible patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.